Impella versus IABP in acute myocardial infarction complicated by cardiogenic shock.
Brunilda AlushiAndel DouedariGeorg FroehligWulf KnieThomas H WursterDavid M LeistnerBarbara Elisabeth StahliHans-Christian MochmannBurkert PieskeUlf LandmesserFlorian KrackhardtCarsten SkurkPublished in: Open heart (2019)
In patients with AMICS, haemodynamic support with the Impella device had no significant effect on 30-day mortality as compared with IABP. In these patients, large randomised trials are warranted to ascertain the effect of Impella on the outcome.
Keyphrases
- acute myocardial infarction
- end stage renal disease
- extracorporeal membrane oxygenation
- ejection fraction
- clinical trial
- chronic kidney disease
- newly diagnosed
- left ventricular assist device
- peritoneal dialysis
- open label
- prognostic factors
- left ventricular
- percutaneous coronary intervention
- cardiovascular events
- study protocol
- randomized controlled trial
- cardiovascular disease
- type diabetes
- heart failure
- double blind
- atrial fibrillation